Adenocarcinoma, Animals, Antineoplastic Combined Chemotherapy Protocols, Biomarkers, Tumor, Female, Fluorouracil, Gene Expression Profiling, Gene Expression Regulation, Neoplastic, Humans, Mice, Inbred NOD, Mice, Knockout, Mice, SCID, Oxaliplatin, Stomach Neoplasms, Survival Analysis, Tumor Burden, Xenograft Model Antitumor Assays
Nat Commun 2021 Aug 10; 12(1):4840
Gastric cancer (GC) is commonly treated by chemotherapy using 5-fluorouracil (5-FU) derivatives and platinum combination, but predictive biomarker remains lacking. We develop patient-derived xenografts (PDXs) from 31 GC patients and treat with a combination of 5-FU and oxaliplatin, to determine biomarkers associated with responsiveness. When the PDXs are defined as either responders or non-responders according to tumor volume change after treatment, the responsiveness of PDXs is significantly consistent with the respective clinical outcomes of the patients. An integrative genomic and transcriptomic analysis of PDXs reveals that pathways associated with cell-to-cell and cell-to-extracellular matrix interactions enriched among the non-responders in both cancer cells and the tumor microenvironment (TME). We develop a 30-gene prediction model to determine the responsiveness to 5-FU and oxaliplatin-based chemotherapy and confirm the significant poor survival outcomes among cases classified as non-responder-like in three independent GC cohorts. Our study may inform clinical decision-making when designing treatment strategies.
Na, Deukchae; Chae, Jeesoo; Cho, Sung-Yup; Kang, Wonyoung; Lee, Ahra; Min, Seoyeon; Kang, Jinjoo; Kim, Min Jung; Choi, Jaeyong; Lee, Woochan; Shin, Dongjin; Min, Ahrum; Kim, Yu-Jin; Lee, Kyung-Hun; Kim, Tae-Yong; Suh, Yun-Suhk; Kong, Seong-Ho; Lee, Hyuk-Joon; Kim, Woo-Ho; Park, Hansoo; Im, Seock-Ah; Yang, Han-Kwang; Lee, Charles; and Kim, Jong-Il, "Predictive biomarkers for 5-fluorouracil and oxaliplatin-based chemotherapy in gastric cancers via profiling of patient-derived xenografts." (2021). Faculty Research 2021. 166.